SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jun 29, 2026

ROIV

Roivant Sciences Ltd.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $22.1M total
Actionable Insight • Neutral

These insider sales are routine and immaterial relative to company size. No bearish signal. Monitor for any catalyst like upcoming FDA decisions or earnings, but this cluster alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
ROIV ▲ +4.04% at T+60d
NEUTRAL call +4.04% · α vs SPY +1.22% · entry $35.39 → $36.82
Entry = T+0 close
Jun 29, 2026
via day close
T+1d
-1.02%
call -1.02% · α -0.88%
$35.03
settled 4mo ago
T+5d
0.00%
call 0.00% · α -0.60%
$35.39
settled 4mo ago
T+20d
-1.89%
call -1.89% · α -0.86%
$34.72
settled 3mo ago
T+60d
+4.04%
call +4.04% · α +1.22%
$36.82
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Two top executives at Roivant Sciences (President & CIO and President & Immunovant CEO) sold a total of $22.15M in open-market shares, following option exercises. This represents only ~0.09% of the company's $24.5B market cap, making it a routine diversification event with no material signal.

Key Financial Metrics

Direction
selling
Total Value
$22.1M
Insiders
2

Key Facts

  • President & CIO Mayukh Sukhatme sold ~1M shares (via two trades on June 25-26) for $34.1M in gross sales, but net open-market sale value is $22.15M after accounting for option exercise costs.
  • President & Immunovant CEO Eric Venker sold 153,766 shares on June 24 for $5.08M, also after exercising options.
  • Total open-market sales of $22.15M equal roughly 0.09% of Roivant's $24.5B market cap, below the 0.1% threshold for materiality.
  • Both executives exercised stock options at $3.85 or $0 strike price before selling, indicating these are pre-planned or tax-related transactions.

Financial Impact

Open-market sales of $22.15M represent 0.09% of market cap - trivial

insider ownershipfloat

Risk Factors

  • Insider sales could accelerate if stock price weakens, but current volume is negligible.
  • No fundamental business risk indicated from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ROIV-1782771812326
23 reports for ROIV
Performance horizon
67% Hit rate @ T+20 4 of 6 directional calls Went positive at some point 6 of 8 best @ T+60▲ +28.81%Mar 28, 2026
Filters
Rows
Reports for ROIV — sortable, filterable
TypeNow
Oct 21, 2026
5d ago
8-K
BULLISH ★ 7/10
$36.80awaiting T+20—$36.05 (−2.04%)
Oct 5, 2026
21d ago
Insider Cluster
BEARISH ★ 4/10
$35.53awaiting T+20—$36.05 (−1.46%)
Sep 17, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$39.77 $33.53▼ −15.69%▼ −15.89%$36.05 (−9.35%)
Sep 17, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$39.77 $33.53▼ −15.69%▼ −15.89%$36.05 (−9.35%)
Sep 17, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$39.77 $33.53▼ −15.69%▼ −15.89%$36.05 (−9.35%)
Sep 1, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$34.18 $36.57▲ +6.99%▲ +7.32%$36.05 (+5.47%)
Aug 27, 2026
8w ago
Press Release
BULLISH ★ 8/10
$37.58 $36.13▼ −3.86%▼ −3.35%$36.05 (−4.07%)
Aug 27, 2026
8w ago
Press Release
BULLISH ★ 8/10
$37.58 $36.13▼ −3.86%▼ −3.35%$36.05 (−4.07%)
Aug 26, 2026
8w ago
Press Release
BULLISH ★ 6/10
$36.75 $38.99▲ +6.10%▲ +4.89%$36.05 (−1.90%)
Aug 6, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$35.12 $34.41▼ −2.02%▼ −2.62%$36.05 (+2.65%)
Showing 10 of 23

US Market Status

Market Closed — Opens in 3h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026